1
|
Deng Y, Wang M, Zhou L, Zheng Y, Li N,
Tian T, Zhai Z, Yang S, Hao Q, Wu Y, et al: Global burden of larynx
cancer, 1990-2017: Estimates from the global burden of disease 2017
study. Aging (Albany NY). 12:2545–2583. 2020.PubMed/NCBI View Article : Google Scholar
|
2
|
Morshed K, Skomra D, Korobowicz E,
Szymański M, Polz-Dacewicz M and Gołabek W: An immunohistochemical
study of cyclin D1 protein expression in laryngeal squamous cell
carcinoma. Acta Otolaryngol. 127:760–769. 2007.PubMed/NCBI View Article : Google Scholar
|
3
|
American Joint Committee on Cancer. Amin
MB, Edge SB, Schilsky RL and Gaspar LE: AJCC cancer staging manual.
Springer, New York, NY, 2017.
|
4
|
Bradford CR, Ferlito A, Devaney KO,
Mäkitie AA and Rinaldo A: Prognostic factors in laryngeal squamous
cell carcinoma. Laryngoscope Investig Otolaryngol. 5:74–81.
2020.PubMed/NCBI View
Article : Google Scholar
|
5
|
Brandstorp-Boesen J, Sørum Falk R, Boysen
M and Brøndbo K: Impact of stage, management and recurrence on
survival rates in laryngeal cancer. PLoS One.
12(e0179371)2017.PubMed/NCBI View Article : Google Scholar
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
7
|
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu
Y, Gong Z, Zhang S, Zhou J, Cao K, et al: Role of tumor
microenvironment in tumorigenesis. J Cancer. 8:761–773.
2017.PubMed/NCBI View Article : Google Scholar
|
8
|
Leesutipornchai T, Ratchataswan T,
Vivatvakin S, Ruangritchankul K, Keelawat S, Kerekhanjanarong V,
Bongsebandhu-Phubhakdi S and Mahattanasakul P: EGFR cut-off point
for prognostic impact in laryngeal squamous cell carcinoma. Acta
Otolaryngol. 140:610–614. 2020.PubMed/NCBI View Article : Google Scholar
|
9
|
Vivatvakin S, Ratchataswan T,
Leesutipornchai T, Ruangritchankul K, Keelawat S, Mahattanasakul P
and Bongsebandhu-Phubhakdi S: MCM-2, Ki-67, and EGFR downregulated
expression levels in advanced stage laryngeal squamous cell
carcinoma. Sci Rep. 11(14607)2021.PubMed/NCBI View Article : Google Scholar
|
10
|
Almadori G, Cadoni G, Galli J, Ferrandina
G, Scambia G, Exarchakos G, Paludetti G and Ottaviani F: Epidermal
growth factor receptor expression in primary laryngeal cancer: An
independent prognostic factor of neck node relapse. Int J Cancer.
84:188–191. 1999.PubMed/NCBI View Article : Google Scholar
|
11
|
Maurizi M, Almadori G, Ferrandina G,
Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti
G, Scambia G and Mancuso S: Prognostic significance of epidermal
growth factor receptor in laryngeal squamous cell carcinoma. Br J
Cancer. 74:1253–1257. 1996.PubMed/NCBI View Article : Google Scholar
|
12
|
Furuta Y, Takasu T, Asai T, Yoshimura S,
Tokuchi F, Shinohara T, Nagashima K and Inuyama Y: Clinical
significance of the epidermal growth factor receptor gene in
squamous cell carcinomas of the nasal cavities and paranasal
sinuses. Cancer. 69:358–362. 1992.PubMed/NCBI View Article : Google Scholar
|
13
|
Marioni G, Staffieri A, Bertolin A,
Giacomelli L, D'Alessandro E, Ottaviano G, Accordi D, Stramare R,
de Filippis C and Blandamura S: Laryngeal carcinoma lymph node
metastasis and disease-free survival correlate with MASPIN nuclear
expression but not with EGFR expression: A series of 108 cases. Eur
Arch Otorhinolaryngol. 267:1103–1110. 2010.PubMed/NCBI View Article : Google Scholar
|
14
|
Cavaliere M, Bisogno A, Scarpa A, D'Urso
A, Marra P, Colacurcio V, De Luca P, Ralli M, Cassandro E and
Cassandro C: Biomarkers of laryngeal squamous cell carcinoma: A
review. Ann Diagn Pathol. 54(151787)2021.PubMed/NCBI View Article : Google Scholar
|
15
|
Gioacchini FM, Alicandri-Ciufelli M,
Magliulo G, Rubini C, Presutti L and Re M: The clinical relevance
of Ki-67 expression in laryngeal squamous cell carcinoma. Eur Arch
Otorhinolaryngol. 272:1569–1576. 2015.PubMed/NCBI View Article : Google Scholar
|
16
|
Cai K, Luo Y, Li L and Liu Y: Expression
and significance of MCM2, Ki-67 and Rb protein in laryngeal
squamous cell carcinomas. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke
Za Zhi. 26:425–428. 2012.PubMed/NCBI(In Chinese).
|
17
|
Re M, Zizzi A, Ferrante L, Stramazzotti D,
Goteri G, Gioacchini FM, Olivieri F, Magliulo G and Rubini C: p63
and Ki-67 immunostainings in laryngeal squamous cell carcinoma are
related to survival. Eur Arch Otorhinolaryngol. 271:1641–1651.
2014.PubMed/NCBI View Article : Google Scholar
|
18
|
Nowinska K, Chmielewska M, Piotrowska A,
Pula B, Pastuszewski W, Krecicki T, Podhorska-Okołow M, Zabel M and
Dziegiel P: Correlation between levels of expression of
minichromosome maintenance proteins, Ki-67 proliferation antigen
and metallothionein I/II in laryngeal squamous cell cancer. Int J
Oncol. 48:635–645. 2016.PubMed/NCBI View Article : Google Scholar
|
19
|
Krecicki T, Jeleń M, Zalesska-Krecicka M
and Szkudlarek T: Ki-67 immunostaining and prognosis in laryngeal
cancer. Clin Otolaryngol Allied Sci. 23:539–542. 1998.PubMed/NCBI View Article : Google Scholar
|
20
|
Kropveld A, Slootweg PJ, Blankenstein MA,
Terhaard CH and Hordijk GJ: Ki-67 and p53 in T2 laryngeal cancer.
Laryngoscope. 108:1548–1552. 1998.PubMed/NCBI View Article : Google Scholar
|
21
|
Roland NJ, Caslin AW, Nash J and Stell PM:
Value of grading squamous cell carcinoma of the head and neck. Head
Neck. 14:224–229. 1992.PubMed/NCBI View Article : Google Scholar
|
22
|
Cordes C, Münzel AK, Rudolph P, Hoffmann
M, Leuschner I and Gottschlich S: Immunohistochemical staining of
Ki-67 using the monoclonal antibody Ki-s11 is a prognostic
indicator for laryngeal squamous cell carcinoma. Anticancer Res.
29:1459–1465. 2009.PubMed/NCBI
|
23
|
Wang N, Huang X and Cheng J: BIRC5
promotes cancer progression and predicts prognosis in laryngeal
squamous cell carcinoma. PeerJ. 10(e12871)2022.PubMed/NCBI View Article : Google Scholar
|
24
|
Zhu Y, Shi X, Zhu X, Diao W and Chen X:
Association between pathological differentiation and survival
outcomes of patients with laryngeal squamous cell carcinoma. Eur
Arch Otorhinolaryngol. 279:4595–4604. 2022.PubMed/NCBI View Article : Google Scholar
|
25
|
Chen P, Yu W, Huang J, Xu H, Li G, Chen X
and Huang Z: Matched-pair analysis of survival in patients with
poorly differentiated versus well-differentiated glottic squamous
cell carcinoma. Oncotarget. 8:14770–14776. 2017.PubMed/NCBI View Article : Google Scholar
|
26
|
Fararouei M, Daneshi N, Mohammadianpanah
Μ, Reza Tabatabaei H, Zare-Bandamiri M and Dianatinasab M: Factors
predicting survival in patients with early stage laryngeal cancer:
A cohort study between 2000 to 2015. J BUON. 22:996–1003.
2017.PubMed/NCBI
|
27
|
Piccirillo JF, Wells CK, Sasaki CT and
Feinstein AR: New clinical severity staging system for cancer of
the larynx. Five-year survival rates. Ann Otol Rhinol Laryngol.
103:83–92. 1994.PubMed/NCBI View Article : Google Scholar
|
28
|
Kitani Y, Kubota A, Furukawa M and Sato K:
Prognostic factors for local control in patients receiving
radiation therapy for early glottic cancer: Anterior commissure
involvement and effect of chemoradiotherapy. Eur Arch
Otorhinolaryngol. 273:1011–1017. 2016.PubMed/NCBI View Article : Google Scholar
|
29
|
Chone CT, Yonehara E, Martins JE, Altemani
A and Crespo AN: Importance of anterior commissure in recurrence of
early glottic cancer after laser endoscopic resection. Arch
Otolaryngol Head Neck Surg. 133:882–887. 2007.PubMed/NCBI View Article : Google Scholar
|
30
|
Hakeem AH, Tubachi J and Pradhan SA:
Significance of anterior commissure involvement in early glottic
squamous cell carcinoma treated with trans-oral CO2 laser
microsurgery. Laryngoscope. 123:1912–1917. 2013.PubMed/NCBI View Article : Google Scholar
|
31
|
Zouhair A, Azria D, Coucke P, Matzinger O,
Bron L, Moeckli R, Do HP, Mirimanoff RO and Ozsahin M: Decreased
local control following radiation therapy alone in early-stage
glottic carcinoma with anterior commissure extension. Strahlenther
Onkol. 180:84–90. 2004.PubMed/NCBI View Article : Google Scholar
|
32
|
Le QT, Fu KK, Kroll S, Ryu JK, Quivey JM,
Meyler TS, Krieg RM and Phillips TL: Influence of fraction size,
total dose, and overall time on local control of T1-T2 glottic
carcinoma. Int J Radiat Oncol Biol Phys. 39:115–126.
1997.PubMed/NCBI View Article : Google Scholar
|
33
|
Bron LP, Soldati D, Zouhair A, Ozsahin M,
Brossard E, Monnier P and Pasche P: Treatment of early stage
squamous-cell carcinoma of the glottic larynx: Endoscopic surgery
or cricohyoidoepiglottopexy versus radiotherapy. Head Neck.
23:823–829. 2001.PubMed/NCBI View
Article : Google Scholar
|
34
|
Allegra E, Saita V, Azzolina A, De Natale
M, Bianco MR, Modica DM and Garozzo A: Impact of the anterior
commissure involvement on the survival of early glottic cancer
treated with cricohyoidoepiglottopexy: A retrospective study.
Cancer Manag Res. 10:5553–5558. 2018.PubMed/NCBI View Article : Google Scholar
|
35
|
Mannelli G, Comini LV, Santoro R, Bettiol
A, Vannacci A, Desideri I, Bonomo P and Piazza C: T1 glottic
cancer: Does anterior commissure involvement worsen prognosis?
Cancers (Basel). 12(1485)2020.PubMed/NCBI View Article : Google Scholar
|
36
|
Dimaras H and Gallie BL: Retinoblastoma
protein, biological and clinical functions. In: Encyclopedia of
Cancer. Schwab M (ed). Springer, Berlin, pp3277-3280, 2011.
|
37
|
Morshed K, Korobowicz E, Skomra D,
Szymanski M, PolzDacewicz M, Gołabek W and Smolen A:
Immunohistochemical study of retinoblastoma protein expression in
laryngeal squamous cell carcinoma according to low and high
overexpression. Bulletin of the Veterinary Institute in Pulawy.
52:675–681. 2008.
|
38
|
Mizokami H, Sawatsubashi M, Tokunaga O and
Shin T: Loss of retinoblastoma protein expression in laryngeal
squamous cell carcinoma. Mod Pathol. 12:47–53. 1999.PubMed/NCBI
|
39
|
Lee LA, Fang TJ, Li HY, Huang CG, Chen TC,
Liao CT, Kang CJ, Chang KP and Yen TC: Low expression of pRB
predicts disease relapse in early glottic cancer treated with
transoral laser microsurgery. Laryngoscope. 129:E220–E226.
2019.PubMed/NCBI View Article : Google Scholar
|
40
|
Raj S, Kesari KK, Kumar A, Rathi B, Sharma
A, Gupta PK, Jha SK, Jha NK, Slama P, Roychoudhury S and Kumar D:
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in
head and neck cancer. Mol Cancer. 21(31)2022.PubMed/NCBI View Article : Google Scholar
|
41
|
Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan
C, Wu Y, Li X, Li X, Li G, et al: Function of the c-Met receptor
tyrosine kinase in carcinogenesis and associated therapeutic
opportunities. Mol Cancer. 17(45)2018.PubMed/NCBI View Article : Google Scholar
|
42
|
Rothenberger NJ and Stabile LP: Hepatocyte
Growth Factor/c-Met signaling in head and neck cancer and
implications for treatment. Cancers (Basel). 9(39)2017.PubMed/NCBI View Article : Google Scholar
|
43
|
Li L, Sun Z, Huang X, Li X, Sun L, Zhang
L, Zhang X, Ye L, Yuan J, Mao L and Li G: Role of c-Met expression
on prognosis of head and neck cancer: A literature review and
meta-analysis. Head Neck. 41:1999–2006. 2019.PubMed/NCBI View Article : Google Scholar
|
44
|
Jiang M, Zhang H, Xiao H, Zhang Z, Que D,
Luo J, Li J, Mao B, Chen Y, Lan M, et al: High expression of c-Met
and EGFR is associated with poor survival of patients with glottic
laryngeal squamous cell carcinoma. Oncol Lett. 15:931–939.
2018.PubMed/NCBI View Article : Google Scholar
|
45
|
Szturz P, Budíková M, Vermorken JB, Horová
I, Gál B, Raymond E, de Gramont A and Faivre S: Prognostic value of
c-MET in head and neck cancer: A systematic review and
meta-analysis of aggregate data. Oral Oncol. 74:68–76.
2017.PubMed/NCBI View Article : Google Scholar
|
46
|
Mo HN and Liu P: Targeting MET in cancer
therapy. Chronic Dis Transl Med. 3:148–153. 2017.PubMed/NCBI View Article : Google Scholar
|
47
|
Shah M, Nunes MR and Stearns V: CDK4/6
inhibitors: Game changers in the management of hormone
receptor-positive advanced breast cancer? Oncology (Williston
Park). 32:216–222. 2018.PubMed/NCBI
|
48
|
Ngamphaiboon N, Chairoungdua A,
Dajsakdipon T and Jiarpinitnun C: Evolving role of novel
radiosensitizers and immune checkpoint inhibitors in
(chemo)radiotherapy of locally advanced head and neck squamous cell
carcinoma. Oral Oncol. 145(106520)2023.PubMed/NCBI View Article : Google Scholar
|